Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Long-Term Investments (2020 - 2025)

Kymera Therapeutics (KYMR) has disclosed Long-Term Investments for 6 consecutive years, with $771.2 million as the latest value for Q4 2025.

  • Quarterly Long-Term Investments rose 112.93% to $771.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $771.2 million through Dec 2025, up 112.93% year-over-year, with the annual reading at $771.2 million for FY2025, 112.93% up from the prior year.
  • Long-Term Investments for Q4 2025 was $771.2 million at Kymera Therapeutics, up from $473.1 million in the prior quarter.
  • The five-year high for Long-Term Investments was $771.2 million in Q4 2025, with the low at $45.3 million in Q2 2021.
  • Average Long-Term Investments over 5 years is $205.2 million, with a median of $119.4 million recorded in 2021.
  • The sharpest move saw Long-Term Investments tumbled 60.16% in 2021, then surged 489.84% in 2024.
  • Over 5 years, Long-Term Investments stood at $125.2 million in 2021, then increased by 21.66% to $152.3 million in 2022, then tumbled by 59.68% to $61.4 million in 2023, then soared by 489.84% to $362.2 million in 2024, then soared by 112.93% to $771.2 million in 2025.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $771.2 million, $473.1 million, and $297.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.